日本語 
FUJIFILM Biotechnologies has introduced ShunzymeX which functions as a precision purification technology that solves one of the most difficult problems encountered in biologics manufacturing. The launch took place at the Festival of Biologics in San Diego.
Downstream purification has always been messy, especially for microbial expressed proteins. Different sizes, different sequences, no standard affinity resin that just works. The result is longer development cycles, inconsistent yields, and purity headaches that slow the path to GMP manufacturing.
ShunzymeX changes the equation. The platform adds an affinity tag to the target protein, enabling purification using off the shelf affinity resins. A proprietary protease then removes the tag cleanly, leaving no residual scar on the final protein. That sounds technical, but the implication is simple. Faster process development and a clearer path to IND enabling milestones.
Also Read: PHCbi Leverages Real-Time Monitoring for Cell Therapy
Developed in collaboration with the University of Edinburgh, the technology is designed to work across multiple expression systems and scale directly to cGMP production.
In a market pushing for speed without compromising quality, this is less about flash and more about fixing fundamentals.
English